As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Here are two brilliant options along those lines: CVS Health ( CVS 0.44%) and Bristol Myers Squibb ( BMY -1.03%). Find out ...

Coverage options include selling price valuation for wine in production and finished products, as well as protection for ...

Bristol Myers Squibb’s third-quarter results benefited from sales of its legacy brands Eliquis and Revlimid, as well as ...

BMS Group (BMS), a re/insurance broker, has introduced BMS Bacchus, a specialised stock throughput insurance solution for ...

In an exclusive chat with The Hindu, on a recent visit to Hyderabad, he discussed India’s growing significance as a site for ...

ALX Oncology Holdings, a Californian immuno-oncology company, has announced the appointment of Alan Sandler as chief medical ...

Analyst Terence Flynn from Morgan Stanley reiterated a Sell rating on Bristol-Myers Squibb (BMY – Research Report) and decreased the ...

The global biopharmaceutical market saw a 2% increase in market capitalization in Q3 2024, led by growth from Bristol-Myers ...

Analyst Evan Seigerman of BMO Capital maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report), boosting the price target ...

The Chicago-based firm earlier announced that its two Phase II EMPOWER trials investigating emraclidine as a once-daily, oral ...